IMPORTANCE Mutations in the titin gene (TTN) cause a wide spectrum of genetic diseases. The interpretation of the numerous rare variants identified in TTN is a difficult challenge given its large size.
T he TTN gene encodes titin, a giant sarcomeric protein, spanning from the Z-disc to the M-band.
1 Titin plays crucial functional and structural roles in the sarcomere.
2
Mutations in the TTN gene cause several different muscle disorders, cardiomyopathies, and combinations of these.
3,4
The skeletal muscle diseases caused by TTN mutations include a wide spectrum of disorders. 5 The late-onset autosomal dominant tibial muscular dystrophy (TMD) is caused by mutations in the last exon (364), which cause a posttranslational pathological cleavage of a larger portion of the C-terminal titin protein. [6] [7] [8] Young-or early-adult-onset recessive distal titinopathy is due to either 2 mutations in the last 2 exons (363-364), or 1 mutation in these exons and a truncating mutation on the other allele. 9 Similarly, 2 C-terminal mutations or 1 C-terminal mutation along with a truncating variant in trans cause an earlyonset recessive limb-girdle muscular dystrophy 2J. [10] [11] [12] Other congenital or early-onset recessive titinopathies comprise disorders with heterogeneous clinical and histological features: congenital centronuclear myopathy, 13, 14 early-onset myopathy with fatal cardiomyopathy, 15 multiminicore disease with heart disease, 16 and childhood-juvenile-onset EmeryDreifuss-like myopathy phenotype without cardiomyopathy.
17
Hereditary myopathy with early respiratory failure (HMERF) represents an increasingly identified, completely different adult-onset myopathy, mainly because of dominant mutations in exon 344.
18
Many additional TTN-related muscular phenotypes are emerging as a consequence of next-generation sequencing (NGS) screening in patients with myopathy. 5 For instance, adult-onset proximal lower limb weakness without ankle dorsiflexion weakness has been described in 2 unrelated patients who had a TMD-causing mutation combined with a second missense mutation. 9, 19 Recently, a novel TTN homozygous truncating mutation was found in a patient with arthrogryposis multiplex congenita and severe axial hypotonia as a form of congenital amyoplasia without cardiac involvement.
20
The mutation occurs within an exon, which seems to be expressed only in the fetal skeletal isoform.
Next-generation sequencing is rapidly being implemented into routine clinical practice, improving the diagnostic rate for patients with neuromuscular diseases. [21] [22] [23] Almost all NGS screenings reveal many rare and private titin variants and their clinical interpretation is particularly challenging. 5, 19, [24] [25] [26] By using MotorPlex (Agilent Technologies), a targeted NGS panel, we screened TTN and the other muscle disease genes in 504 patients with skeletal muscle disorders. 25, 26 Here, we describe the approach used for the NGS data interpretation and we propose a workflow for a more straightforward and reproducible interpretation of the clinical meaning of titin variants.
Methods

Patients
We recruited 504 European patients from 10 clinical centers, mainly adults (mean [SD] age of recruitment, 39.04 [19.09] years) with skeletal muscle disorders. The patients had not received diagnoses despite extensive diagnostic investigations performed according to the observed phenotype. All the patients or their legal guardians provided written informed consent. The study, approved by the ethics committee of the Universitá della Campania "Luigi Vanvitelli," was performed in accordance with the Declaration of Helsinki.
Molecular Analysis
Genomic DNA was extracted from the peripheral blood by phenol/chloroform purification. Next-generation sequencing libraries were prepared using MotorPlex, as previously described. 25, 26 An in-house pipeline [25] [26] [27] was used to analyze the raw data. We focused on patients with previously reported TTN mutations or with at least a single TTN truncating variant. Missense variants were explicitly studied in a single large recessive family only (family X). Further possible causative variants in genes other than titin were ruled out by a segregation analysis.
Titin gene mutated exons were amplified by polymerase chain reaction using M13-tailed primers. M13 primers were used to perform Sanger sequencing using an ABI PRISM 3130XL Genetic Analyzer (Applied Biosystems).
Direct-zol RNA MiniPrep Kit (Zymo Research) was used to extract RNA from muscle biopsies. Complementary DNA (cDNA) synthesis was performed using RevertAid H Minus Reverse Transcriptase (Thermo Scientific). Reversetranscription polymerase chain reactions were performed using primers designed with Primer3 software and a DreamTaq DNA Polymerase (Thermo Scientific). Copy number variant analysis was performed using a custom array-comparative genomic hybridization, MotorChip 28 (Agilent Technologies). Sequence variants in TTN are described according to the coding DNA reference sequence (LRG_391t1), covering transcript variant-IC (NM_001267550.1). An in silico analysis of missense variants and the prediction of their deleterious effects were performed by homology modeling in DeepView/Swiss-PdbViewer, version 4.1.0 (GlaxoSmithKline R&D and Swiss Institute of Bioinformatics) 29 crystal structure is available (2NZI). 30 The models were visualized using POV-Ray, version 3.7 (Persistence of Vision Raytracer Pty Ltd); (http://www.povray.org).
Muscle Imaging, Histological Studies, and Western Blot Analysis
Muscle magnetic resonance imaging of the lower limbs using 1.5-T magnetic resonance scanners (Siemens and Philips) 31 and histological and histochemical examinations in muscle biopsies followed standard procedures. 32 Western blotting (WB) of muscle biopsy samples was performed according to standard methods. 9 Two previously described in-house-generated antibodies (rabbit polyclonal antibody M10-1 11 and mouse monoclonal antibody 11-4-3 9 ) were used to detect the titin M10 domain, followed by horseradish peroxidase-conjugated secondary antibodies (Dako) and enhanced chemilumescent detection using the Pierce SuperSignal West Femto substrate (Thermo Fisher).
9
Results
In an extensive study of 504 mainly adult, patients who had not received a genetic diagnosis and were presenting with clinical signs of muscular dystrophy, congenital myopathy, or other skeletal muscle disorders, we identified 9 novel patients (1.8%) with titinopathy and 4 patients (0.8%) with very likely diseasecausing TTN mutations. The clinical details of each patient are summarized in Table 1 and described in the eAppendix in the Supplement.
Patients With Previously Described Mutations
We identified disease-associated mutations in the TTN gene in 3 patients (0.6%). The most common mutation responsible for the HMERF phenotype (p.Cys31712Arg in exon 344) 18 was identified in 2 cases (I and II). Patient I was a man in his late 50s with no family history for neuromuscular disorders. He presented with a progressive distal weakness in the lower limbs (onset at 40 years) and a restrictive respiratory insufficiency due to respiratory muscle weakness.
Patient II was a man in his mid-50s presenting with a distal myopathy (onset in his mid-40s with myalgia and exercise intolerance). Although pulmonary function test results were only minimally impaired, muscle biopsy results revealed typical histopathological features seen in HMERF, including cytoplasmic bodies and rimmed vacuoles.
A previously reported TMD mutation (p.Ile35947Asn) 33 was identified in compound heterozygosity with a nonsense mutation in a Belgian woman in her early 40s (patient III). This patient has been described elsewhere. 34 In brief, she shows an earlier onset (at 30 years) and a more severe phenotype compared with previously reported patients with TMD who carried the same missense variant in heterozygosity.
33
Patients With Biallelic Protein Truncating Variants
In 4 patients (0.8%), protein truncating variants (PTVs) were identified on both alleles. In a man in his early 30s with healthy parents and siblings (patient IV), we found a splice site variant (c.107377 + 1G>A in intron 362) on the maternal allele and a nonsense variant (p.Tyr21719* in exon 312) on the paternal allele. Since childhood, the patient had shown mildly progressive generalized muscular weakness. He received a diagnosis of dilated cardiomyopathy without arrhythmias in his late teens. Messenger RNA analyses confirmed the splicing effect of the intronic variant (eFigure in the Supplement). Western blotting analyses showed a reduced intensity of small Cterminal titin protein fragments and the presence of an additional band due to the splicing defect ( Figure 1) .
A 34-year-old Belgian patient (patient V) with an unremarkable family history harbored the p.Glu11945Argfs*6 variant in exon 164 and the c.25063 + 1G>A variant in intron 87 in compound heterozygosity. Since childhood, the patient had shown a slowly progressive generalized muscular weakness and gait abnormalities with frequent falling. In silico predictions confirmed that c.25063 + 1G>A would result in a splicing defect. Further messenger RNA and WB analyses were not performed because of the unavailability of muscle tissue.
Two further biallelic PTVs were identified in patient VI (p.Val26358Phefs*4 and p.Gln35879*, the latter recently reported as a Balkan-Middle East founder mutation 34, 35 ) and in 2 siblings (cases VIIa and VIIb) (p.Cys9322* and p.Arg35800Glnfs*10). Patient VI was a woman in her mid-50s presenting in her early 30s with frequent tripping. Her family history was unremarkable. The disease worsened and the patient has required a cane to walk for the last 5 years. Echocardiography results in her early 50s showed mild left ventricular hypokinesia and a mildly reduced ejection fraction (43%).
The index case of family VII was a woman in her early 50s (VIIa), with onset in adulthood (in her early 30s) characterized by walking difficulty and distal lower limb muscle weakness. No signs of respiratory or cardiac involvement were detected at a recent follow-up (2016) . Patient VIIb, a sibling, showed similar clinical and histological features.
Patients With a Single Heterozygous Protein Truncating Variant
In 1 additional patient (patient VIII) harboring the heterozygous p.Arg35800Glnfs*10 in exon 363, protein analysis results showed a severe reduction with the C-terminal titin antibodies, indicating truncating mutations on both alleles as previously reported in patients with limb-girdle muscular dystrophy 2J.
9 No additional variants were detected by MotorPlex, and MotorChip did not reveal any copy number variants. The patient had presented with difficulties in running and Achilles' tendon contractures since the preteen years. The weakness in the lower extremities worsened in the early 30s. No signs of cardiomyopathy were detected on heart ultrasonography. In family IX, the proband was a teenage boy who presented with hypotonia and congenital torticollis at birth. He had delayed motor milestones, reaching independent walking after the toddler years. He was referred to the neuromuscular unit as a child because of a proximal and distal weakness. The patient, as well as his similarly affected sibling, harbored a single-nucleotide duplication (p.Arg26562Thrfs*12) on the maternal allele. In addition, 2 missense variants were identified on the paternal allele. In particular, a c.18970A>C causing a substitution of a threonine with a proline at position 6324 was identified. The mutated amino acid is located on the external surface of a β strand in an Ig-domain in the Iband region, probably affecting the stability ( Figure 2A ). The second detected variant was a c.94015A>G leading to a substitution of a threonine at position 31339 with an alanine in an Fn3 domain (A-band portion of titin). The amino acid substitution may affect the interaction with ligands in this region ( Figure 2B ). A comparative genomic hybridization array excluded the presence of copy number variants in the proband and WB results showed a reduced intensity of C-terminal M10 fragments ( Figure 1B ).
Patients With Rare Missense Variants
Because rare missense variants were found in most analyzed patients, we focused on a single recessive family (family X) in whom 2 rare variants segregated with the observed phenotype. The 2 patients were siblings (mid-40s and mid-50s, respectively) and showed a slowly progressive distal myopathy with onset in the second decade. At the latest neurological examination, the patients walked with a waddling gait and bilateral steppage. Their serum creatine kinase levels were normal. No heart or respiratory involvement was observed. Both siblings harbored 2 compound heterozygous missense variants: p.Asn32797Ser and p.Trp33529Arg. The former is located in an Fn3 domain in the A-band portion of titin, and in silico studies predicted that the amino acid is located on the external surface of the domain, possibly affecting the binding to the interactors. The latter variant is in an Ig-domain, which is located just before Ser/Thr kinase domain (TK). The amino acid change probably affects the folding of the domain (Figure 2 ). No further clearly or potentially damaging variants were detected by MotorPlex (not even in additional causative or candidate genes) and MotorChip studies did not reveal any causative deletion or duplication. A segregation study confirmed that none of the 3 unaffected siblings were compound heterozygous for these TTN missense variants. Western blotting results revealed a normal C-terminal titin pattern, as expected ( Figure 1 ).
Discussion
Because of its size, many rare or private variants are usually identified in the titin gene by NGS analyses. 5 The correct interpretation of these variants is a critical challenge for making a diagnosis for patients affected by neuromuscular disorders. 5 Although mainly truncating mutations have been identified in patients with titinopathy, missense variants may similarly have a crucial role, as also suggested by our data (Figure 3 ).
For the interpretation of genetic findings in TTN, we have developed a workflow (Figure 3 ) based on 3 categories of sequence variants: (1) previously reported mutations, (2) truncating variants, and (3) missense changes and on deep phenotyping (ie, a comprehensive and precise evaluation of phenotypic abnormalities in which each component of the clinical phenotype is observed and described).
36 Although the limited number of patients with titinopathy described so far has hampered the identification of specific and unique hallmarks for each TTN-related disease, significant key points have been reported ( Table 2 ). The integration of structured clinical data with genetic variations is crucial for a correct evaluation of TTN findings, as detailed below.
Previously Reported Mutations
If previously reported disease-causing mutations are identified, they may easily address the diagnosis of a titinopathy; however, segregation studies and a deep phenotyping are mandatory for a correct genotype-phenotype correlation and for proper genetic counselling. In the presence of a previously reported HMERF variant (eg, p.Cys31712Arg), a respiratory involvement and/or the presence of cytoplasmic bodies and myofibrillar changes (seen in patient I and II, respectively) confirm the diagnosis of titinopathy.
5,18
The clinical interpretation of mutations in exon 364, previously associated with TMD (like the p.Ile35947Asn in patient III), is more complex. These mutations cause either a dominant, mild, and late-onset distal leg phenotype, or recessive phenotypes. [7] [8] [9] 11 Muscle imaging is mandatory and often very informative (Table 2 ). 
Protein Truncating Variants
Identifying 2 truncating variants in trans results in a diagnosis of titinopathy, which may be corroborated by a WB showing the absence or a severe reduction of the C-terminal protein (patient IV or previously reported patients 9, 34 ). However, a complete molecular characterization of variants affecting the canonical or noncanonical splice sites by cDNA or protein studies is suggested.
Biallelic truncating mutations have been so far associated with a wide range of phenotypes, showing heterogeneous clinical and histological features. However, a primary cardiac involvement is often seen and peculiar imaging findings seem to characterize congenital or early onset titinopathies.
Clinically evaluating single heterozygous truncating variants is more complex (Figure 3) . Increasing evidence is indicating that titin truncating variants cause recessive skeletal muscle disorders. 9, 15, 16, 34 In the presence of monoallelic PTVs, we suggest performing a WB analysis that represents the most valuable and potentially conclusive test, as it is the only available tool able to predict the presence of further elusive truncating variants in trans (as seen in patient VIII and in a previously reported patient 9 ).
Why are there elusive variants in TTN? First, the huge size of the TTN gene and its complex structure, due to a 10-kb triplicate region where 9 exons are repeated 3 times, may hamper an exhaustive gene analysis by NGS, resulting in low-covered or noncovered regions and thus in unidentified mutations. Second, additional elusive mutations may be deep intronic or structural variants. Currently available bioinformatics tools 37 combined with customized comparative genomic hybridization arrays 28,38 . The computed molecular surface is semitransparent gray and the secondary structure is shown with yellow β strands and red α helices. The mutated residue is shown as CPK. A, Position of p.Thr6324Pro using the most similar structure available in the Protein Data Bank (3B43). The mutated residue is located inaβstrand. The mutation to proline will induce steric restrictions most probably causing a reduced stability and a structural disruption. B, p.Thr31339Ala modeled using the structure 2NZI of titin domains A168-A170. The change from threonine to alanine is predicted in a loop and will probably not interfere with the structure. However, the hydroxyl group on the sidechain of threonine allows for hydrogen bonding with other molecules. The amino acid substitution may alter interactions with TTN ligands in this specific region. C, Position of p.Asn32797Ser using the structure 2NZI. The mutated amino acid, one of the first residues in the domain, is on the surface of the model and it seems not to cause any important structural change. It will probably affect the binding to the interactors of this domain. D, Position of p.Trp33529Arg using the structure 2JBO. The tryptophan residue p.Trp33529 is almost totally buried in the hydrophobic core of the protein. The change to a positively charged arginine will probably be detrimental for the structural stability and will lead to an unfolding of this domain. However, a positional effect and an incomplete and agedependent penetrance (probably related to other genetic or environmental factors) may explain the lack of any cardiac symptoms in some individuals with mono or biallelic PTVs (eg, patient V and VIII). 41 A systematic follow-up to evaluate the cardiac status of such individuals, as well as their asymptomatic relatives who carry truncating variants, is highly recommended.
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Missense Variants
The clinical significance of missense variants in TTN represents a major issue related to NGS investigation in the field of neuromuscular disorders. 5 A WB analysis is not effective in the presence of missense variants, as demonstrated in cases IX and X. The evaluation of TTN missense variants should reflect the current genetic guidelines. 42 A segregation analysis and/or in silico predictions can only suggest a pathogenic or a noncausative effect of a missense variant.
42
In the presence of monoallelic truncating variants, as well as of missense variants, the possible causative effect of mutations in genes other than titin has to be ruled out and the presence of the aforementioned key clinical points has to be assessed by deep phenotyping.
However, the definitive proof of pathogenicity for missense variants can only be established by functional tests, segregation studies in very large families, and/or identifying unrelated patients or families with the same mutations. The interpretation of TTN missense variants may also benefit from the establishment of clinical and research consortia able to combine cohorts of patients into larger groups.
43
Limitations
Our study has limitations. First, we enrolled, in a multicenter study, patients with clinically and genetically heterogenous conditions and specific clinical studies (magnetic resonance imaging or cardiac tests) were unavailable or not performed for some patients.
Second, we report missense variants with an unconfirmed causative role (cases IX and X). Although further studies are needed to attribute causality to missense changes, reporting possible causative variants is an effective strategy to improve consistency in the interpretation of molecular findings in titin. Ultimately, the proposed workflow is meant for interpreting titin variants in a mendelian disorder. The possible role of titin variants as modifiers or within a digenic or multigenic disease is not discussed here.
Conclusions
An increasing number of rare, ultrarare, and private variants in the titin gene is detected in any sequencing approach, and NGS has dramatically expanded the spectrum of skeletal muscle disorders associated with causative mutations in TTN.
5 Our workflow results in a greater understanding and more consistent interpretation of titin variants by neurologists, pediatricians, and geneticists less familiar with the titin gene and titinopathies.
eAppendix: Clinical Data
Patient I
Patient I was a man in his late 50s. He was born from non-consanguineous parents and his family history was negative for neuromuscular disorders. The patient presented first symptoms at the age of 40 years, complaining of progressive distal weakness in the lower limbs. Over the years he showed progressive involvement of axial muscles and later onset of proximal weakness initially at upper limbs and subsequently also at lower limbs. Muscle MRI confirmed severe fatty degeneration of gluteus, quadriceps, femoral biceps, and paraspinal muscles. Cardiac function was normal.
Respiratory evaluations showed a restrictive respiratory pattern. At the last assessment, the patient showed severe weakness and hypotrophy of the proximal muscles in the upper limbs (MRC 3), especially of deltoid and infraspinatus. He was not able to raise his arms over the head. Distal strength in the hands was normal. At lower limbs he showed proximal weakness (MRC iliopsoas 3 and quadriceps 4) and severe distal weakness (MRC dorsiflexion 0 and plantarflexion 3). He also had ankle contractions and a waddling gait with bilateral foot-drop. Muscle biopsy showed a dystrophic pattern with severe connective tissue increase and fiber necrosis.
Patient II
Patient II was a man in his mid-50s presenting with an adult onset distal myopathy. Since 2008, he had complained of myalgia in the lower limbs and exercise intolerance. At the last assessment, the patient showed a severe weakness of the neck flexors, peroneal and distal upper limb muscles and a mild to moderate involvement of pelvic muscles. The patient displayed no heart involvement, except for very frequent supraventricular heart beats. Pulmonary function tests were only minimally impaired. Creatine kinase (CK) was slightly increased (2-3X). A mixed pattern was observed on EMG. Muscle biopsy revealed myopathic findings, including cytoplasmic bodies in a few fibers and rare autophagic vacuoles. His mother died in her late 60s from an ischemic heart attack, but had gait difficulties since age 40.
Patient III
Patient III has been extensively described in Evilä et al. 2016 (ref.33 -family E) .
Patient IV
Since his childhood the patient has difficulty in running, fatigability and toe-walking. He was first showed mild left ventricular hypokinesia and mildly reduced ejection fraction (43%), progressing to 35% after 4 years. In her first 50s, spirometry was normal.
Patients VIIa and VIIb
Patient VIIa was a woman in her early 50s with an onset (walking difficulty) in her early 30s, mainly due to distal lower limb muscle weakness. She was first admitted for examinations in her mid-30s and showed marked (MRC 2/5) tibialis anterior muscle weakness and hypotrophy, mild 
Patient VIII
The patient had presented with difficulties in running and Achilles' tendon contractures since the preteen years. Weakness in lower extremities worsened in the early 30s. CK was elevated (between 400 and 700 UI/l). No signs of cardiomyopathy were detected on heart ultrasound. Muscle biopsy showed myopathic changes with prominent internal nuclei and fiber type disproportion. Some fibers displayed likely autophagic vacuoles and core-like areas were also reported.
At the latest examination, the patient showed hypotrophy of lower limb muscles, mild hyperlordosis and Achille's tendon contractures. He walked with a waddling and steppage gait. Weakness was mainly present in hip adductors and flexors (MRC 2), knee flexors and hip extensors (MRC 3), tibialis anterior, iliopsoas, biceps and triceps brachii (MRC 4). Muscle MRI showed asymmetric fatty replacement in paraspinal, obturator externus and glutei muscles, diffuse involvement of thigh muscles (including semitendinosus, gracilis and sartorius) with peculiar relative sparing of adductor magnus, rectus femoris and vastus lateralis and widespread fatty replacement of lower leg muscles with sparing of flexor and extensor digitorum longus, tibialis posterior and to a lesser extent soleus.
Patient IXa and IXb
The proband was a teenage boy who had hypotonia and congenital torticollis at birth. He had delayed motor milestones and frequent falls. He was referred to the neuromuscular unit as a child because of a proximal and distal weakness. At the examination in 2015, he presented winged scapulae, pectus excavatum and pes cavus. He had a waddling gait, was unable to rise from the floor, and presented proximal weakness in the upper limbs, proximo-distal weakness in the lower limbs, neck flexor weakness and mild facial weakness. Muscle biopsy showed myopathic changes with internal nuclei, fibers presenting mini-multicores, and type 1 fiber predominance.
A similar phenotype was observed in his affect sister (IXb).
Patient Xa and Xb
Both the affected siblings show a slowly progressive distal myopathy with an onset in the second decade. At the latest neurological examination, the patients walked with a waddling gait and bilateral steppage. Distal weakness in both upper and lower limbs (tibialis anterior) was observed.
Muscle MRI showed fatty infiltration in all muscles of thigh (IIb and III) as well as in tibialis anterior (III-IV) and in soleus (IIb -III). Myopathic changes were seen at EMG. A muscle biopsy showed severe increase of connective tissue, muscle fiber variability, several rounded hypotrophic and rare rounded hypertrophic fibers, numerous internal nuclei and the presence of rare vacuoles.
CK was normal and no heart or respiratory involvement was observed.
eFigure. Muscle cDNA analysis in patient IV confirms that the variant c.107377+1G>A causes a misplicing
The variant c.107377+1G>A, identified in patient IV, actives two different exonic cryptic acceptor sites with the subsequent activation of cryptic branch sites.
Two altered transcripts were identified, one missing the last 69 nucleotides of exon 362 and the second one missing the last 7 nucleotides of the same exon.
